Shari Logan
Family · Parker, CONPI 1760715825
Payments from drug & device makers
Across 142 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$469
- Novo Nordisk$386
- AstraZeneca$377
- Lilly USA, LLC$198
- Pfizer$182
- Amgen$172
- plus $880 from 24 others
What the payments were for
- Food & beverage$2,64799%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $469 |
| Novo Nordisk | 22 | $386 |
| AstraZeneca | 22 | $377 |
| Lilly USA, LLC | 13 | $198 |
| Pfizer | 10 | $182 |
| Amgen(2 entities) | 9 | $172 |
| Exact Sciences | 5 | $119 |
| Astellas Pharma US Inc | 3 | $81 |
| GSK | 4 | $60 |
| Sanofi Pasteur Inc. | 2 | $52 |
| Eisai Inc. | 3 | $50 |
| Bayer | 2 | $41 |
| Medtronic | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Lucid Diagnostics Inc. | 2 | $36 |
| Abiomed | 1 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Edwards Lifesciences | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Boehringer Ingelheim | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Optos, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$124
How this compares
$2,663 in reported general payments places this provider in the 90th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $63,519 |
| FarxigaDapagliflozin Propanediol | 42 | $58,028 |
| EliquisApixaban | 33 | $34,477 |
| JardianceEmpagliflozin | 15 | $22,085 |
| XareltoRivaroxaban | 15 | $20,568 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,954 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,594 |
| Levothyroxine Sodium | 275 | $2,494 |
| Atorvastatin Calcium | 205 | $1,836 |
| Rosuvastatin Calcium | 106 | $1,818 |
| Celecoxib | 18 | $1,694 |
| Omeprazole | 75 | $1,395 |
| SynthroidLevothyroxine Sodium | 19 | $1,350 |
| Lisinopril | 206 | $1,234 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $386 | $63,51952 claims |
| AstraZenecaFarxiga | $377 | $58,02842 claims |
| PfizerEliquis | $182 | $34,47733 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $26 | $28,03926 claims |
| GSKAnoro Ellipta | $60 | $5,59412 claims |
| AbbVieSynthroid | $469 | $1,35019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,182 family providers in Colorado.
Other family in Parker
- Diana ByrdParker$19K
- Jette HogenmillerParker$19K
- Charmin BroughtonParker$11K
- Laura GrahamLakewood$1.6M
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
- Teal MeffordThornton$63K
- Jacquita JordanColorado Springs$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.